Antisense conjugates for decreasing expression of DMPK
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
A61K-047/48
A61K-031/7088
C07K-016/44
C12N-015/113
A61J-001/14
A61K-031/713
C07K-016/28
출원번호
US-0385724
(2013-03-14)
등록번호
US-9610362
(2017-04-04)
국제출원번호
PCT/US2013/031718
(2013-03-14)
국제공개번호
WO2013/138662
(2013-09-19)
발명자
/ 주소
Armstrong, Dustin D.
출원인 / 주소
Valerion Therapeutics, LLC
대리인 / 주소
Ropes & Gray LLP
인용정보
피인용 횟수 :
1인용 특허 :
100
초록▼
The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugate
The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugates and kits comprising these conjugates are also considered. Wherein the conjugates are suitable for delivery to muscle cells.
대표청구항▼
1. A conjugate comprising a) an antisense oligonucleotide that hybridizes to a DMPK transcript wherein the oligonucleotide is capable of: i) mediating RNase H-mediated degradation following hybridization to the DMPK transcript, and/orii) preventing a protein or nucleic acid from binding to the DMPK
1. A conjugate comprising a) an antisense oligonucleotide that hybridizes to a DMPK transcript wherein the oligonucleotide is capable of: i) mediating RNase H-mediated degradation following hybridization to the DMPK transcript, and/orii) preventing a protein or nucleic acid from binding to the DMPK transcript; andb) an antibody or antigen binding fragment: wherein the antibody or antigen binding fragment comprises a heavy chain variable domain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 13, or a humanized variant thereof, and a light chain variable domain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 14, or a humanized variant thereof; wherein the antibody or antigen binding fragment promotes delivery of the antisense oligonucleotide into muscle cells. 2. The conjugate of claim 1, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 13, or a humanized variant thereof, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 14, or a humanized variant thereof. 3. The conjugate of claim 1, wherein the antisense oligonucleotide is a gapmer or a morpholino. 4. The conjugate of claim 1, wherein the antisense oligonucleotide hybridizes to CUG repeats to at least a portion of the 3′UTR of a DMPK transcript. 5. The conjugate of claim 1, wherein the antisense oligonucleotide hybridizes to any one of SEQ ID NOs: 24-27. 6. The conjugate of claim 1, wherein the antisense oligonucleotide is a single stranded oligonucleotide. 7. The conjugate of claim 1, wherein the antisense oligonucleotide comprises 14, 15, 16, 17, 18, 19, or 20 nucleotides. 8. The conjugate of claim 1, wherein the antisense oligonucleotide comprises 14-30 nucleotides. 9. The conjugate of claim 1, wherein the antisense oligonucleotide comprises a central portion of at least 7 nucleotides, which central portion of at least 7 nucleotides is capable of mediating RNase H-mediated degradation following hybridization to RNA. 10. The conjugate of claim 1, wherein the antisense oligonucleotide sterically inhibits binding of MBNL1 to a nucleotide sequence. 11. The conjugate of claim 1, wherein the antisense oligonucleotide prevents a protein or nucleic acid from binding to any one of SEQ ID NOs: 24-27. 12. The conjugate of claim 9, wherein the central portion of at least 7 nucleotides is composed of unmodified DNA nucleotides, modified nucleotides, or a combination thereof. 13. The conjugate of claim 12, wherein modified nucleotides are phosphorothioate nucleotides. 14. The conjugate of claim 1, wherein the antisense oligonucleotide comprises two wing portions, each of which flank the central portion. 15. The conjugate of claim 14, wherein each of the two wing portions comprises at least 3 nucleotides. 16. The conjugate of claim 14, wherein all of the nucleotides of each of the two wings comprise modified nucleotides of the same class of modification selected from one of the following: locked nucleic acid (LNA) nucleotides, 2′-O-methoxyelthyl nucleotides, 2′-O-methyl nucleotides, a peptide nucleic acid, a hexitol nucleic acid, an N3′-P5′-phosphoroamidate, or conformationally restricted nucleotides (CRN). 17. The conjugate of claim 16, wherein the antisense oligonucleotide that binds to the DMPK transcript comprises the primary nucleotide sequence set forth in any of SEQ ID NOs: 9-12 or 22-23. 18. The conjugate of claim 17, wherein the two wing portions of the antisense oligonucleotide comprise LNA nucleotides or 2′-O-methoxyethyl nucleotides. 19. The conjugate of claim 17, wherein the two wing portions of the antisense oligonucleotide comprise CRN nucleotides. 20. The conjugate of claim 1, wherein the conjugate comprises an antigen binding fragment, and the antisense oligonucleotide is conjugated to the C-terminus of the antigen binding fragment. 21. The conjugate of claim 1, wherein the conjugate comprises an antigen binding fragment, and the antisense oligonucleotide is conjugated to the N-terminus of the antigen binding fragment. 22. The conjugate of claim 1, wherein the conjugate comprises an antibody, and the antisense oligonucleotide is conjugated to an Fc portion of the antibody. 23. The conjugate of claim 22, wherein a free cysteine is added to the antibody or antigen binding fragment, and the antisense oligonucleotide is conjugated by site directed chemical conjugation via the free cysteine. 24. The conjugate of claim 1, wherein the ratio of antisense oligonucleotide conjugated per antibody or antigen binding fragment is 1:1. 25. The conjugate of claim 1, wherein the antisense oligonucleotide hybridizes to at least a portion of the 3′UTR region of the DMPK transcript. 26. The conjugate of claim 25, wherein the antisense oligonucleotide hybridizes to a DMPK transcript and promotes degradation of the transcript. 27. The conjugate of claim 1, wherein the conjugate further comprises a muscle blind polypeptide (MBNL1), or a functional fragment thereof comprising all four zinc finger motifs, interconnected to the antibody or antigen fragment thereof. 28. A conjugate comprising a MBNL1 polypeptide or a functional fragment thereof comprising all four zinc finger motifs;an antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 13, or a humanized variant thereof, and a light chain variable domain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 14, or a humanized variant thereof; wherein the antibody or antigen binding fragment promotes delivery of the antisense oligonucleotide into muscle cells; andan antisense oligonucleotide that hybridizes to a DMPK transcript; wherein the oligonucleotide is capable of: i) mediating RNase H-mediated degradation following hybridization to the DMPK transcript, and/orii) preventing a protein or nucleic acid from binding to the DMPK transcript. 29. A composition comprising the conjugate of claim 1 formulated in a physiologically acceptable carrier. 30. The composition of claim 29, wherein said composition is substantially pyrogen-free. 31. A method of treating myotonic dystrophy, comprising administering to a patient in need thereof a conjugate of claim 1. 32. A method of promoting entry into muscle cells, comprising contacting cells or administering to a patient a conjugate of claim 1. 33. A method of treating myotonic dystrophy, comprising administering to a patient in need thereof two therapeutics, either simultaneously or concurrently, and wherein the therapeutics comprise: a conjugate of claim 1; anda chimeric polypeptide comprising: (a) an MBNL1 polypeptide or a functional fragment thereof comprising all four zinc finger motifs; and(b) an antibody or antigen binding fragment; wherein the antibody or antigen binding fragment comprises a heavy chain variable domain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 13, or a humanized variant thereof, and a light chain variable domain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 14, or a humanized variant thereof; wherein the antibody or antigen binding fragment promotes delivery of the antisense oligonucleotide into muscle cells. 34. A kit comprising a first container comprising the conjugate of claim 1; anda second container comprising a chimeric polypeptide comprising: (a) an MBNL1 polypeptide or a functional fragment thereof comprising all four zinc finger motifs; and(b) an antibody or antigen binding fragment; wherein the antibody or antigen binding fragment comprises a heavy chain variable domain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 13, or a humanized variant thereof, and a light chain variable domain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 14, or a humanized variant thereof; wherein the antibody or antigen binding fragment promotes delivery of the antisense oligonucleotide into muscle cells. 35. The kit of claim 34, comprising instructions for research or therapeutic use. 36. The kit of claim 34, comprising suitable buffers to reconstitute a lyophilized agent in either the first or the second container. 37. The conjugate of claim 1, wherein the antisense oligonucleotide is a gapmer, and wherein the antisense oligonucleotide comprises phosphorothioate nucleotides and locked nucleic acid (LNA) nucleotides. 38. The conjugate of claim 37, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 13, or a humanized variant thereof, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 14, or a humanized variant thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (100)
Tkachuk Zenovy (Kiev SUX) Kvasyuk Eugeny (Kiev SUX) Matsuka Gennady (Kiev SUX) Mikhailopulo Igor (Kiev SUX), (2′-5′) oligoadenylate analogues useful as inhibitors of host-v5.-graft response.
Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), 2′,5′-phosphorothioate oligoadenylates and their covalent conjugates with polylysine.
Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
Ohtsuka Eiko (Sappro JPX) Inoue Hideo (Sappro JPX) Morisawa Hirokazu (Kawasaki JPX) Shibahara Susumu (Kawasaki JPX) Mukai Sachiko (Kawasaki JPX) Nishihara Tohru (Kurashiki JPX), Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and st.
Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke Shee L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Armstrong, Dustin D., Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1(MTM1) polypeptides.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA) Eder Paul S. (Iowa City IA) Dagle John M. (Iowa City IA), Methods for blocking the expression of specifically targeted genes.
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA), Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled.
Buhr Chris (Daly City CA) Matteucci Mark (Burlingame CA) Bischofberger Norbert W. (San Carlos CA) Froehler Brian (Belmont CA), Nucleoside 5′-methylene phosphonates.
Froehler Brian C. (Belmont CA) Buhr Chris A. (Daly City CA), Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues.
Meyer ; Jr. Rich B. (Woodinville WA) Adams A. David (Snohomish WA) Petrie Charles R. (Woodinville WA), Oligo (aa
상세보기
Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
Imbach Jean-Louis (Montpellier FRX) Gosselin Gilles J. M. (Montpellier FRX), Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.